Is Staphylococcus lugdunensis susceptible to cefepime?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, Staphylococcus lugdunensis is generally susceptible to cefepime. Cefepime is a fourth-generation cephalosporin that has good activity against this coagulase-negative staphylococcal species. S. lugdunensis is typically more susceptible to beta-lactam antibiotics than other coagulase-negative staphylococci, showing a susceptibility profile more similar to Staphylococcus aureus.

Key Points to Consider

  • According to the study published in Circulation 1, S. lugdunensis is uniformly susceptible in vitro to most antibiotics, which supports its susceptibility to cefepime.
  • The European Heart Journal study 1 also notes that S. lugdunensis is always methicillin susceptible, further indicating its likelihood of being susceptible to cefepime.
  • When treating S. lugdunensis infections, cefepime can be used at standard dosing (typically 1-2g IV every 8-12 hours in adults with normal renal function, adjusted for renal impairment).
  • However, it's crucial to perform antimicrobial susceptibility testing to confirm sensitivity before definitive therapy, as methicillin-resistant strains, although less common, can occur.
  • If methicillin resistance is detected, alternative agents such as vancomycin, daptomycin, or linezolid would be more appropriate choices than cefepime.

From the Research

Susceptibility of Staphylococcus lugdunensis to Cefepime

  • The provided studies do not directly address the susceptibility of Staphylococcus lugdunensis to cefepime 2, 3, 4, 5, 6.
  • However, study 2 mentions that Staphylococcus lugdunensis remains susceptible to most antibiotics, but it does not specifically mention cefepime.
  • Study 3 discusses the use of cefepime in the management of hospitalized patients with pneumonia, but it does not provide information on its effectiveness against Staphylococcus lugdunensis.
  • Study 4 reports that coagulase-negative staphylococci, including Staphylococcus lugdunensis, are sensitive to cefotaxime, but it does not provide information on cefepime.
  • Study 5 investigates the pharmacodynamics of cefepime against methicillin-resistant Staphylococcus aureus, but it does not address Staphylococcus lugdunensis.
  • Study 6 reports on skin and soft tissue infections caused by Staphylococcus lugdunensis, but it does not provide information on the susceptibility of the organism to cefepime.

Antibiotic Susceptibility of Staphylococcus lugdunensis

  • Staphylococcus lugdunensis is generally susceptible to most antibiotics, including penicillin G, oxacillin, and other antibiotics tested in study 2.
  • However, the resistance to penicillin varies widely, and methicillin resistance is still rare 2.
  • Study 6 reports that all isolates of Staphylococcus lugdunensis were susceptible to most of the antibiotics tested, including oxacillin.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019

Research

Cefepime: a review of its use in the management of hospitalized patients with pneumonia.

American journal of respiratory medicine : drugs, devices, and other interventions, 2003

Research

Resistant coagulase negative staphylococci from clinical samples.

The Indian journal of medical research, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.